Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $32.8M
- Enterprise value
- $32.8M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $8.94
- 52-wk low
- $0.04
- Beta
- —
- Shares out
- 7.9M
5-year trend
What this company does
Item 1. Business. Q/C Technologies, Inc. (the “Company”) has historically been engaged in the development and commercialization of therapeutic platforms based on well-defined biological targets, including Isomyosamine and Supera-CBD. More recently, the Company has shifted its business strategy to focus on energy-efficient blockchain and cryptocurrency infrastructure through quantum-class laser-based computing. The Company’s core strategy is centered on leveraging an exclusive global licensing agreement with LightSolver Ltd. (“LightSolver”) to deploy innovative laser processing units (“LPUs”), including the Company-branded qc-LPU100™ (the “qc-LPU100”). These systems are designed to harness…
AI summary unavailable — showing raw filing excerpt
Generated from QCLS's filing dated 2026-04-15
Key risks
Item 1A. Risk Factors. An investment in our Common Stock involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks described below, together with other information in this Annual Report on Form 10-K and the other information and documents we file with the SEC. Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described below, any one or more of which could, directly, or indirectly, cause our actual financial condition and operating results to vary materially from past, or from anticipated future, financial…
AI summary unavailable — showing raw filing excerpt
Generated from QCLS's filing dated 2026-04-15
Profitability
Return on equity
-53.5%
77.6%Return on assets
-28.2%
74.1%Leverage
Debt / equity
0.89×
24.9%Debt / assets
47.2%
13.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-1.2M | -10.5% | — |
Q4 2025 2025-12-31 | — | — | $-5.9M | -185.6% | — |
Q3 2025 2025-09-30 | — | — | $-2.8M | -45.7% | — |
Q2 2025 2025-06-30 | — | — | $-1.8M | +81.2% | — |
Q1 2025 2025-03-31 | — | — | $-1.1M | +88.5% | — |
Q4 2024 2024-12-31 | — | — | $-2.1M | — | — |
Q3 2024 2024-09-30 | — | — | $-1.9M | -17.9% | — |
Q2 2024 2024-06-30 | — | — | $-9.6M | -129.5% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
In Vitro & In Vivo Diagnostic Substances · SIC 2835
Your notes
Keep private notes on QCLS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$5.5K
Insider selling
$0
Net activity
+$5.5K
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns QCLS
Institutional value
$954.3K
Total shares held
276.6K
Distinct holders
8
-11 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | JANE STREET GROUP, LLC | 126.2K | $435.3K | +85.7K (+211.7%) | Added |
| 2 | UBS Group AG | 78.0K | $269.1K | +60.6K (+347.6%) | Added |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 37.5K | $129.4K | — | New |
| 4 | DIMENSIONAL FUND ADVISORS LP | 19.1K | $65.8K | +0 (+0.0%) | No change |
| 5 | VANGUARD FIDUCIARY TRUST CO | 15.6K | $53.7K | — | New |
| 6 | BNP PARIBAS FINANCIAL MARKETS | 300 | $1.0K | -900 (-75.0%) | Trimmed |
| 7 | BlackRock, Inc. | 19 | $66 | +0 (+0.0%) | No change |
| 8 | Wilmington Savings Fund Society, FSB | 1 | $3 | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once QCLS's latest filing finishes processing.